Analyst Ratings For BEXIMCO PHARMAC/S GDR REGS (LON:BXP)
Today, Northland Securities reiterated its Buy rating on BEXIMCO PHARMAC/S GDR REGS (LON:BXP).
There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on BEXIMCO PHARMAC/S GDR REGS (LON:BXP) is Buy with a consensus target price of GBX 79.50 per share, a potential .
Some recent analyst ratings include
- 7/30/2018-Northland Securities Reiterated Rating of Buy.
- 4/3/2018-Northland Capital Partners Reiterated Rating of Buy.
About BEXIMCO PHARMAC/S GDR REGS (LON:BXP)
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients. The company offers allergic disorder, analgesic and antipyretic, anti-infective, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, muscloskeletal, oncology, respiratory, skin care, vitamin and mineral supplement, and other products. It also provides contract manufacturing services. The company offers its products in approximately 50 countries. Beximco Pharmaceuticals Limited was founded in 1976 and is headquartered in Dhaka, Bangladesh.
Recent Trading Activity for BEXIMCO PHARMAC/S GDR REGS (LON:BXP)
Shares of BEXIMCO PHARMAC/S GDR REGS closed the previous trading session at 48,25 +0,25 0,52 % with 102408 shares trading hands.
